Your Feed

Filter by
See content from
Back to the latest
Thumbnail for Real‑World Results for Menin Inhibitors in Hard‑to‑Treat AML | Kuo-Kai Chin, MD
Playlist: ASH 2025

Real‑World Results for Menin Inhibitors in Hard‑to‑Treat AML | Kuo-Kai Chin, MD

Video details & playlist
Dear fellow caregivers and MM sufferers, I have been using ChatGPT to help me understand blood work and bone marrow results for the last year of treatment, which began with my wife's kidney failure in January of 2025 and the subsequent diagnose of MM. Her recovery has been spectacular with minimal side effects. With help from Chat, I have composed the following letter (a bit long perhaps) in preparation for our January 6th oncologist appointment. Please comment as you see fit, particularly as to whether or not I am being reasonable. Current Therapy (as of Dec 2025) • Anti-CD38 monoclonal antibody infusion every 2 weeks • Lenalidomide 25 mg, days 1–21 of 28-day cycle • Corticosteroids: weekly oral dexamethasone plus IV methylprednisolone with infusions • Zoledronic acid monthly • IVIG monthly for hypogammaglobulinemia ________________________________________ Objective Evidence of Disease Control Bone Marrow • No detectable malignant plasma cells • Hematopoiesis recovered CBC Trends (Jan–Dec 2025) • Early severe cytopenias resolved • Sustained hemoglobin ~13–15 g/dL • WBC stable • Platelets fluctuating but largely safe (120–220k) • Persistent macrocytosis consistent with treatment effect SPEP / Immunoglobulins • No rising monoclonal spike • Persistent hypogammaglobulinemia (gamma globulin ~0.5 g/dL) • Pattern consistent with treatment-related immune suppression, not progression Ferritin • Elevated but declining over time • Consistent with inflammation/transfusion/steroid exposure rather than disease activity ________________________________________ Clinical Interpretation • Current laboratory abnormalities are more consistent with cumulative treatment toxicity than active myeloma • Patient appears to be in a deep, durable response approaching functional remission • Ongoing full-intensity therapy may be contributing to: o Immune suppression requiring IVIG o Cytopenias and macrocytosis o Steroid-related adverse effects ________________________________________ Proposed Stepwise De-escalation (Risk-Minimizing) 1. Steroids (highest priority) • Reduce weekly dexamethasone dose by ≥50% or discontinue oral weekly dosing • Rationale: minimal added disease control in deep responders, high toxicity burden 2. Lenalidomide optimization • Reduce dose (e.g., 10–15 mg) • Or modify schedule (e.g., 14 days on / 14 days off) • Rationale: marrow stress, cytopenias, immune suppression 3. Infusion spacing • Consider extending monoclonal antibody infusions to every 4 weeks • Alternatively, trial close-monitoring pause 4. Bone agent reassessment • Consider spacing zoledronic acid to every 3 months or discontinuation if no active bone disease 5. IVIG reassessment • Goal: reduce need by allowing immune reconstitution following therapy de-escalation ________________________________________ Monitoring Plan to Mitigate Risk • Monthly CBC, SPEP, free light chains • Symptom surveillance • Rapid re-escalation if biochemical or clinical relapse detected ________________________________________ Key Question for Discussion Can we preserve disease control while reducing treatment-related toxicity and improving immune recovery through a cautious, stepwise de-escalation strategy?
Thumbnail for What Happens When You Add Mosunetuzumab + Polatuzumab to CAR‑T (axi‑cel)? | Jay Spiegel, MD
Playlist: ASH 2025

What Happens When You Add Mosunetuzumab + Polatuzumab to CAR‑T (axi‑cel)? | Jay Spiegel, MD

Video details & playlist
Avatar
Iliana • Admin
Myelodysplastic Syndromes Discussion • December 24
From everyone at HealthTree, we extend our warm wishes for a peaceful holiday season, surrounded by
From everyone at HealthTree, we extend our warm wishes for a peaceful holiday season, surrounded by those who support and care for you. ❤️ We are sincerely grateful to every patient, caregiver, loved one, specialist, and collaborator whose voice and presence shaped our community this year. Your experiences, trust, and engagement help guide our work and strengthen efforts to improve the quality of life and access to better treatments for all patients. Thank you for being part of HealthTree and for allowing us to support you on your journey. With appreciation, The HealthTree Team
Avatar
Iliana • Admin
Myelofibrosis Discussion • December 24
A Holiday Thank You to Our Community
AI-generated title
From everyone at HealthTree, we extend our warm wishes for a peaceful holiday season, surrounded by those who support and care for you. ❤️ We are sincerely grateful to every patient, caregiver, loved one, specialist, and collaborator whose voice and presence shaped our community this year. Your experiences, trust, and engagement help guide our work and strengthen efforts to improve the quality of life and access to better treatments for all patients. Thank you for being part of HealthTree and for allowing us to support you on your journey. With appreciation, The HealthTree Team
Avatar
Iliana • Admin
Acute Myeloid Leukemia Discussion • December 24
Sending Holiday Wishes and Gratitude
AI-generated title
From everyone at HealthTree, we extend our warm wishes for a peaceful holiday season, surrounded by those who support and care for you. ❤️ We are sincerely grateful to every patient, caregiver, loved one, specialist, and collaborator whose voice and presence shaped our community this year. Your experiences, trust, and engagement help guide our work and strengthen efforts to improve the quality of life and access to better treatments for all patients. Thank you for being part of HealthTree and for allowing us to support you on your journey. With appreciation, The HealthTree Team
Avatar
Iliana • Admin
Multiple Myeloma Discussion • December 24
Our Holiday Gratitude for This Community
AI-generated title
From everyone at HealthTree, we extend our warm wishes for a peaceful holiday season, surrounded by those who support and care for you. ❤️ We are sincerely grateful to every patient, caregiver, loved one, specialist, and collaborator whose voice and presence shaped our community this year. Your experiences, trust, and engagement help guide our work and strengthen efforts to improve the quality of life and access to better treatments for all patients. Thank you for being part of HealthTree and for allowing us to support you on your journey. With appreciation, The HealthTree Team
Thumbnail for Non-Covalent vs Covalent BTK Inhibitors: What’s Best of Patients | Jennifer Woyach, MD
Playlist: ASH 2025

Non-Covalent vs Covalent BTK Inhibitors: What’s Best of Patients | Jennifer Woyach, MD

Video details & playlist
Thumbnail for SMART STOP Trial: Targeted Drugs Before Chemo in B-Cell Lymphoma? | Jason Westin, MD
Playlist: ASH 2025

SMART STOP Trial: Targeted Drugs Before Chemo in B-Cell Lymphoma? | Jason Westin, MD

Video details & playlist